MedTrace Logo

A Study of Blood-stage Controlled Human Plasmodium Falciparum Malaria Infection in Tanzania

NCT04788862 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-05-24

No results posted yet for this study

Summary

This will be a single-centre, open label trial to determine the safety and feasibility of CHMI model using Plasmodium falciparum-infected cryopreserved erythrocytes administered to healthy Tanzanian adults with varying prior exposure to P. falciparum.

Conditions

Interventions

BIOLOGICAL

P. falciparum infected erythrocytes

Chloroquine sensitive P. falciparum 3D7-infected red blood cells, thawed and prepared under strict aseptic conditions, will be used as a challenge agent.

Sponsors & Collaborators

  • Ifakara Health Institute

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Angela Minassian, Dr · University of Oxford

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-18
Primary Completion
2023-02-24
Completion
2023-02-24

Countries

  • Tanzania

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04788862 on ClinicalTrials.gov